Hyperthermic isolated limb perfusion

Evolving concepts in the treatment of extremity soft tissue sarcomas

James Lewis, Geremy Sanders, Douglas Reintgen, G. Douglas Letson

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Hyperthermic isolated limb perfusion is an established limb salvage therapy used in the treatment of extremity soft tissue sarcomas. The article reviews recent literature regarding this treatment modality. RECENT FINDINGS: Hyperthermic isolated limb perfusion continues to evolve. Over the last year one large trial has been published evaluating overall outcomes. Recent literature has focused on the efficacy of decreasing tumor necrosis factor-α dosage. Studies have demonstrated similar efficacy between lower doses of tumor necrosis factor-α with decreased side-effects. The role of external beam radiation and hyperthermic isolated limb perfusion is still being established. A new study demonstrated decreased local recurrence rates for patients when surgery and external beam radiation follow hyperthermic isolated limb perfusion. Much is known about short-term complications and morbidity associated with this treatment; however, new documentation is available on long-term quality of life issues as well as post-traumatic responses in these patients. Recent studies also evaluated the palliative value of hyperthermic isolated limb perfusion in stage IV soft tissue sarcomas with locally advanced disease. SUMMARY: Hyperthermic isolated limb perfusion continues to garner increased awareness. There are disparities between European and American results, due to differences between treatment regimens. Hyperthermic isolated limb perfusion for patients with extremity sarcomas who would otherwise require amputation is a viable option. To date the best results are from institutions who treat a large number of patients using tumor necrosis factor-α and melphelan.

Original languageEnglish (US)
Pages (from-to)558-562
Number of pages5
JournalCurrent Opinion in Orthopaedics
Volume17
Issue number6
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Sarcoma
Extremities
Perfusion
Therapeutics
Tumor Necrosis Factor-alpha
Radiation
Salvage Therapy
Limb Salvage
Amputation
Documentation
Quality of Life
Morbidity
Recurrence

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Hyperthermic isolated limb perfusion : Evolving concepts in the treatment of extremity soft tissue sarcomas. / Lewis, James; Sanders, Geremy; Reintgen, Douglas; Letson, G. Douglas.

In: Current Opinion in Orthopaedics, Vol. 17, No. 6, 01.12.2006, p. 558-562.

Research output: Contribution to journalReview article

Lewis, James ; Sanders, Geremy ; Reintgen, Douglas ; Letson, G. Douglas. / Hyperthermic isolated limb perfusion : Evolving concepts in the treatment of extremity soft tissue sarcomas. In: Current Opinion in Orthopaedics. 2006 ; Vol. 17, No. 6. pp. 558-562.
@article{7fef857aae354052abf45d0239550c03,
title = "Hyperthermic isolated limb perfusion: Evolving concepts in the treatment of extremity soft tissue sarcomas",
abstract = "PURPOSE OF REVIEW: Hyperthermic isolated limb perfusion is an established limb salvage therapy used in the treatment of extremity soft tissue sarcomas. The article reviews recent literature regarding this treatment modality. RECENT FINDINGS: Hyperthermic isolated limb perfusion continues to evolve. Over the last year one large trial has been published evaluating overall outcomes. Recent literature has focused on the efficacy of decreasing tumor necrosis factor-α dosage. Studies have demonstrated similar efficacy between lower doses of tumor necrosis factor-α with decreased side-effects. The role of external beam radiation and hyperthermic isolated limb perfusion is still being established. A new study demonstrated decreased local recurrence rates for patients when surgery and external beam radiation follow hyperthermic isolated limb perfusion. Much is known about short-term complications and morbidity associated with this treatment; however, new documentation is available on long-term quality of life issues as well as post-traumatic responses in these patients. Recent studies also evaluated the palliative value of hyperthermic isolated limb perfusion in stage IV soft tissue sarcomas with locally advanced disease. SUMMARY: Hyperthermic isolated limb perfusion continues to garner increased awareness. There are disparities between European and American results, due to differences between treatment regimens. Hyperthermic isolated limb perfusion for patients with extremity sarcomas who would otherwise require amputation is a viable option. To date the best results are from institutions who treat a large number of patients using tumor necrosis factor-α and melphelan.",
author = "James Lewis and Geremy Sanders and Douglas Reintgen and Letson, {G. Douglas}",
year = "2006",
month = "12",
day = "1",
doi = "10.1097/01.bco.0000247367.49201.6b",
language = "English (US)",
volume = "17",
pages = "558--562",
journal = "Current Orthopaedic Practice",
issn = "1940-7041",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Hyperthermic isolated limb perfusion

T2 - Evolving concepts in the treatment of extremity soft tissue sarcomas

AU - Lewis, James

AU - Sanders, Geremy

AU - Reintgen, Douglas

AU - Letson, G. Douglas

PY - 2006/12/1

Y1 - 2006/12/1

N2 - PURPOSE OF REVIEW: Hyperthermic isolated limb perfusion is an established limb salvage therapy used in the treatment of extremity soft tissue sarcomas. The article reviews recent literature regarding this treatment modality. RECENT FINDINGS: Hyperthermic isolated limb perfusion continues to evolve. Over the last year one large trial has been published evaluating overall outcomes. Recent literature has focused on the efficacy of decreasing tumor necrosis factor-α dosage. Studies have demonstrated similar efficacy between lower doses of tumor necrosis factor-α with decreased side-effects. The role of external beam radiation and hyperthermic isolated limb perfusion is still being established. A new study demonstrated decreased local recurrence rates for patients when surgery and external beam radiation follow hyperthermic isolated limb perfusion. Much is known about short-term complications and morbidity associated with this treatment; however, new documentation is available on long-term quality of life issues as well as post-traumatic responses in these patients. Recent studies also evaluated the palliative value of hyperthermic isolated limb perfusion in stage IV soft tissue sarcomas with locally advanced disease. SUMMARY: Hyperthermic isolated limb perfusion continues to garner increased awareness. There are disparities between European and American results, due to differences between treatment regimens. Hyperthermic isolated limb perfusion for patients with extremity sarcomas who would otherwise require amputation is a viable option. To date the best results are from institutions who treat a large number of patients using tumor necrosis factor-α and melphelan.

AB - PURPOSE OF REVIEW: Hyperthermic isolated limb perfusion is an established limb salvage therapy used in the treatment of extremity soft tissue sarcomas. The article reviews recent literature regarding this treatment modality. RECENT FINDINGS: Hyperthermic isolated limb perfusion continues to evolve. Over the last year one large trial has been published evaluating overall outcomes. Recent literature has focused on the efficacy of decreasing tumor necrosis factor-α dosage. Studies have demonstrated similar efficacy between lower doses of tumor necrosis factor-α with decreased side-effects. The role of external beam radiation and hyperthermic isolated limb perfusion is still being established. A new study demonstrated decreased local recurrence rates for patients when surgery and external beam radiation follow hyperthermic isolated limb perfusion. Much is known about short-term complications and morbidity associated with this treatment; however, new documentation is available on long-term quality of life issues as well as post-traumatic responses in these patients. Recent studies also evaluated the palliative value of hyperthermic isolated limb perfusion in stage IV soft tissue sarcomas with locally advanced disease. SUMMARY: Hyperthermic isolated limb perfusion continues to garner increased awareness. There are disparities between European and American results, due to differences between treatment regimens. Hyperthermic isolated limb perfusion for patients with extremity sarcomas who would otherwise require amputation is a viable option. To date the best results are from institutions who treat a large number of patients using tumor necrosis factor-α and melphelan.

UR - http://www.scopus.com/inward/record.url?scp=33750549063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750549063&partnerID=8YFLogxK

U2 - 10.1097/01.bco.0000247367.49201.6b

DO - 10.1097/01.bco.0000247367.49201.6b

M3 - Review article

VL - 17

SP - 558

EP - 562

JO - Current Orthopaedic Practice

JF - Current Orthopaedic Practice

SN - 1940-7041

IS - 6

ER -